Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Share-based Compensation (2022 - 2026)

Phathom Pharmaceuticals (PHAT) has disclosed Share-based Compensation for 5 consecutive years, with $5.5 million as the latest value for Q1 2026.

  • For Q1 2026, Share-based Compensation changed 0.11% year-over-year to $5.5 million; the TTM value through Mar 2026 reached $28.7 million, up 19.83%, while the annual FY2025 figure was $28.7 million, 19.43% up from the prior year.
  • Share-based Compensation hit $5.5 million in Q1 2026 for Phathom Pharmaceuticals, down from $5.6 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $19.3 million in Q4 2023 and bottomed at $5.5 million in Q1 2026.
  • Average Share-based Compensation over 5 years is $7.2 million, with a median of $6.1 million recorded in 2024.
  • Year-over-year, Share-based Compensation skyrocketed 189.92% in 2023 and then plummeted 65.35% in 2024.
  • Phathom Pharmaceuticals' Share-based Compensation stood at $6.7 million in 2022, then surged by 189.92% to $19.3 million in 2023, then tumbled by 65.35% to $6.7 million in 2024, then fell by 16.11% to $5.6 million in 2025, then fell by 1.35% to $5.5 million in 2026.
  • According to Business Quant data, Share-based Compensation over the past three periods came in at $5.5 million, $5.6 million, and $9.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.